ISB News

The Cancer Paradox

“Paradoxes have been suppressed in cancer research because they challenge paradigms and they’re not good for business,” said Dr. Sui Huang, a cancer researcher and professor at ISB. “But they play a central role in understanding therapy.”

Huang hosted a video Q&A recently where he discussed what he calls the cancer paradox.

“The central paradox in cancer is that treatment often backfires,” he said. Traditional cancer therapies — chemotherapy and radiation — shrink tumors. However, at the same time and despite those beneficial effects, those very same therapies prepare the ground for tumors to recur. “That means cancer therapy can actually promote tumor progression,” he said.

Huang is focused on using the theory of complex systems and applying it to cancer research to better understand the fundamental principles that drive cancer and govern why some cancers respond to therapy while others do not.

Understanding the mechanism of what treatments can backfire will, Huang says, open a new avenue for therapy and treatments. “What we’ve been doing so far is doubling down. We have an ineffective therapy, and then we come up with more powerful ways of killing. It’s one-dimensional linear thinking.”

Instead, he says: “We need to kill the tumor without making it stronger.”

You can watch Huang’s full 18-minute video at the top of this page, or you can watch his answers to individual questions below.

NOTE: If you are watching with no sound, you can enable captions with the “CC” button.

What is the cancer paradox?

Length: 2 minutes, 32 seconds

What are long-held cancer perceptions that should be amended?

Length: 1 minute, 56 seconds

What should someone do if diagnosed with cancer?

Length: 2 minutes, 11 seconds

How does cancer treatment promote perturbation?

Length: 2 minutes, 30 seconds

What is the relationship between inflammation and cancer?

Length: 2 minutes, 24 seconds

How is immunotherapy changing the landscape of cancer treatment?

Length: 2 minutes, 5 seconds

Recent Articles

  • Understanding, Preventing and Treating Long-Term Effects of COVID: RECOVER Study Enrolling Patients from Pacific Northwest

    As part of a massive nationwide effort, ISB is leading a multi-site consortium for the NIH RECOVER (Researching COVID to Enhance Recovery) Initiative. The Pacific Northwest consortium is made up of ISB, Providence, Swedish, and University of Washington School of Medicine.

  • Spotlight on ISB Education graphic

    2021-22 School Year ISB Education Highlights

    From planning, creating and executing workshops for educators to forging new relationships to elevate students, the ISB Education team has been in high gear. Each month throughout the 2021-2022 academic year, we will highlight some of the top projects the team is working on.

  • Jim Heath AACR Academy Fellow

    Dr. Jim Heath Named Fellow of AACR Academy Class of 2022

    Dr. Jim Heath was announced as a newly elected Fellow of the American Academy for Cancer Research (AACR) Academy Class of 2022. “I am honored and humbled to be recognized as part of this renowned group of researchers who have done so much to move our understanding of cancer forward,” Heath said.